[Pathogenesis and therapeutic advances of peripheral T-cell lymphoma].
Rinsho Ketsueki
; 63(6): 626-634, 2022.
Article
en Ja
| MEDLINE
| ID: mdl-35831198
ABSTRACT
According to the recently revised WHO classification, peripheral T-cell lymphomas (PTCL) can be classified into up to 30 subtypes. Because the majority of these subtypes were rare cancers, their pathophysiology was not well understood. However, technological advancements including multi-omics approaches such as genomic and gene expression analyses have made significant progress in understanding the pathophysiology of PTCL. Based on the results of these basic studies, the classification of T-cell lymphomas has been changed. Furthermore, new markers discovered through genomic analysis and gene expression analysis are being incorporated into the diagnostic processes of PTCL. Furthermore, multiple new drugs were approved to treat patients of PTCL. Clinical trials are also being carried out as first-line treatments to test the efficacy to combine these new drugs with conventional treatments.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Linfoma de Células T
/
Linfoma de Células T Periférico
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
Ja
Revista:
Rinsho Ketsueki
Año:
2022
Tipo del documento:
Article